Your browser doesn't support javascript.
loading
Linked experimental and modelling approaches for tablet property predictions.
Jolliffe, Hikaru G; Ojo, Ebenezer; Mendez, Carlota; Houson, Ian; Elkes, Richard; Reynolds, Gavin; Kong, Angela; Meehan, Elizabeth; Becker, Felipe Amado; Piccione, Patrick M; Verma, Sudhir; Singaraju, Aditya; Halbert, Gavin; Robertson, John.
Afiliación
  • Jolliffe HG; EPSRC CMAC Future Manufacturing Research Hub, Technology and Innovation Centre, 99 George Street, Glasgow G1 1RD, UK; Strathclyde Institute of Pharmacy & Biomedical Sciences (SIPBS), University of Strathclyde, Glasgow G4 0RE, UK.
  • Ojo E; EPSRC CMAC Future Manufacturing Research Hub, Technology and Innovation Centre, 99 George Street, Glasgow G1 1RD, UK; Strathclyde Institute of Pharmacy & Biomedical Sciences (SIPBS), University of Strathclyde, Glasgow G4 0RE, UK.
  • Mendez C; EPSRC CMAC Future Manufacturing Research Hub, Technology and Innovation Centre, 99 George Street, Glasgow G1 1RD, UK; Strathclyde Institute of Pharmacy & Biomedical Sciences (SIPBS), University of Strathclyde, Glasgow G4 0RE, UK.
  • Houson I; EPSRC CMAC Future Manufacturing Research Hub, Technology and Innovation Centre, 99 George Street, Glasgow G1 1RD, UK; Strathclyde Institute of Pharmacy & Biomedical Sciences (SIPBS), University of Strathclyde, Glasgow G4 0RE, UK.
  • Elkes R; GlaxoSmithKline R&D, Park Road, Ware, Herts SG12 0DP, UK.
  • Reynolds G; Pharmaceutical Technology & Development, Operations, AstraZeneca, Macclesfield SK10 2NA, UK.
  • Kong A; Pfizer Worldwide Research and Development, Groton, CT 0634, USA.
  • Meehan E; Pharmaceutical Technology & Development, Operations, AstraZeneca, Macclesfield SK10 2NA, UK.
  • Becker FA; Pharmaceutical R&D, F. Hoffmann-La Roche AG, Grenzacherstrasse 124, 4070 Basel, Switzerland.
  • Piccione PM; Pharmaceutical R&D, F. Hoffmann-La Roche AG, Grenzacherstrasse 124, 4070 Basel, Switzerland.
  • Verma S; Drug Product Development, Takeda Pharmaceuticals International Co., 35 Landsdowne St., Cambridge, MA 02139, USA.
  • Singaraju A; Synthetic Molecule Design and Development, Eli Lilly and Company, Lilly Research Laboratories, Indianapolis, IN 46285, USA.
  • Halbert G; EPSRC CMAC Future Manufacturing Research Hub, Technology and Innovation Centre, 99 George Street, Glasgow G1 1RD, UK; Strathclyde Institute of Pharmacy & Biomedical Sciences (SIPBS), University of Strathclyde, Glasgow G4 0RE, UK.
  • Robertson J; EPSRC CMAC Future Manufacturing Research Hub, Technology and Innovation Centre, 99 George Street, Glasgow G1 1RD, UK; Strathclyde Institute of Pharmacy & Biomedical Sciences (SIPBS), University of Strathclyde, Glasgow G4 0RE, UK. Electronic address: j.robertson@strath.ac.uk.
Int J Pharm ; 626: 122116, 2022 Oct 15.
Article en En | MEDLINE | ID: mdl-35987318
ABSTRACT
Recent years have seen the advent of Quality-by-Design (QbD) as a philosophy to ensure the quality, safety, and efficiency of pharmaceutical production. The key pharmaceutical processing methodology of Direct Compression to produce tablets is also the focus of some research. The traditional Design-of-Experiments and purely experimental approach to achieve such quality and process development goals can have significant time and resource requirements. The present work evaluates potential for using combined modelling and experimental approach, which may reduce this burden by predicting the properties of multicomponent tablets from pure component compression and compaction model parameters. Additionally, it evaluates the use of extrapolation from binary tablet data to determine theoretical pure component model parameters for materials that cannot be compacted in the pure form. It was found that extrapolation using binary tablet data - where one known component can be compacted in pure form and the other is a challenging material which cannot be - is possible. Various mixing rules have been evaluated to assess which are suitable for multicomponent tablet property prediction, and in the present work linear averaging using pre-compression volume fractions has been found to be the most suitable for compression model parameters, while for compaction it has been found that averaging using a power law equation form produced the best agreement with experimental data. Different approaches for estimating component volume fractions have also been evaluated, and using estimations based on theoretical relative rates of compression of the pure components has been found to perform slightly better than using constant volume fractions (that assume a fully compressed mixture). The approach presented in this work (extrapolation of, where necessary, binary tablet data combined with mixing rules using volume fractions) provides a framework and path for predictions for multicomponent tablets without the need for any additional fitting based on the multicomponent formulation composition. It allows the knowledge space of the tablet to be rapidly evaluated, and key regions of interest to be identified for follow-up, targeted experiments that that could lead to an establishment of a design and control space and forgo a laborious initial Design-of-Experiments.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Química Farmacéutica / Modelos Teóricos Tipo de estudio: Prognostic_studies / Risk_factors_studies Idioma: En Revista: Int J Pharm Año: 2022 Tipo del documento: Article País de afiliación: Reino Unido

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Química Farmacéutica / Modelos Teóricos Tipo de estudio: Prognostic_studies / Risk_factors_studies Idioma: En Revista: Int J Pharm Año: 2022 Tipo del documento: Article País de afiliación: Reino Unido